AnalgeSiC and appEtite-stimulating Effects of caNnabigerol and THC (ASCENT)
NCT ID: NCT04859296
Last Updated: 2025-08-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
20 participants
INTERVENTIONAL
2023-02-15
2026-12-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Cannabidiol on Lean Body Mass in Patients Receiving Chemotherapy
NCT04585841
CBD, Nutrient Metabolism and Energy Intake
NCT05618756
Cannabis for Obesity Trial
NCT06137365
Physiological and Appetitive Effects of CBD Supplementation
NCT05774574
Individual Dietary Counseling Based on Taste-tests in Patients With Hematological Cancer in Cytostatic Therapy
NCT05364359
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
0 mg CBG, 0 mg THC
Placebo
Vaporized placebo
Low strength CBG
5 mg CBG, 0 mg THC
Low CBG
Vaporized CBG (5 mg)
High strength CBG
15 mg CBG, 0 mg THC
High CBG
Vaporized CBG (15 mg)
Low strength THC
0 mg CBG, 5 mg THC
Low THC
Vaporized THC (5 mg)
High strength THC
0 mg CBG, 30 mg THC
High THC
Vaporized THC (15 mg)
Low strength CBG + Low strength THC
5 mg CBG + 5 mg THC
Low CBG
Vaporized CBG (5 mg)
Low THC
Vaporized THC (5 mg)
Low strength CBG + High strength THC
5 mg CBG + 15 mg THC
Low CBG
Vaporized CBG (5 mg)
High THC
Vaporized THC (15 mg)
High strength CBG + Low strength THC
15 mg CBG + 5 mg THC
High CBG
Vaporized CBG (15 mg)
Low THC
Vaporized THC (5 mg)
High strength CBG + High strength THC
15 mg CBG + 15 mg THC
High CBG
Vaporized CBG (15 mg)
High THC
Vaporized THC (15 mg)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Vaporized placebo
Low CBG
Vaporized CBG (5 mg)
High CBG
Vaporized CBG (15 mg)
Low THC
Vaporized THC (5 mg)
High THC
Vaporized THC (15 mg)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* • Report occasional use of cannabis (cannabis use between ≥ biweekly and ≤ 3 days per week) over the month prior to screening
* Not currently seeking treatment for their cannabis use
* Have a Body Mass Index from 18.5 - 34kg/m2.
* Able to perform all study procedures
* Must be using a contraceptive (hormonal or barrier methods)
* Females must not be lactating
Exclusion Criteria
* Any other Axis I disorder
* • Current use of any medications within 14 days or 5 half-lives of administration (whichever is longer) except for hormonal contraceptives in females. If a medication is taken once a participant is enrolled, sessions will be suspended for 14 days or 5 half-lives after administration (whichever is longer)
* If medical history, physical and psychiatric examination, or laboratory tests performed during the screening process are not within the normal range and / or reveal any significant illness (e.g., hypertension) as judged by the study physician and to put the participant at greater risk of experiencing adverse events due to completion of study procedures.
* Current pain
* Pregnancy is exclusionary due to the possible effects of the study medication on fetal development.
* History of an allergic reaction or adverse reaction to cannabis is exclusionary.
* History of respiratory illness or current respiratory illness
* Currently enrolled in another research protocol
* Not using a contraceptive method (hormonal or barrier methods)
* Insensitivity to the cold water stimulus of the Cold Pressor Test
* Any disorders that might make cannabis administration hazardous are exclusionary, as determined by the evaluating physician
21 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Center for Medicinal Cannabis Research
OTHER
University of California, Los Angeles
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ziva D. Cooper, PhD
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ziva D Cooper, PhD
Role: PRINCIPAL_INVESTIGATOR
University of California, Los Angeles
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California, Los Angeles
Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21-000208
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.